Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
112 hedge funds and large institutions have $901M invested in Genomic Health, Inc. in 2015 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 14 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 113 → 112 (-1)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
6% less capital invested
Capital invested by funds: $963M → $901M (-$61.7M)
80% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$5.12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.23M |
| 3 |
MFWM
Motley Fool Wealth Management
Alexandria,
Virginia
|
+$3.23M |
| 4 |
BC
Broadfin Capital
New York
|
+$2.38M |
| 5 |
JP Morgan Chase
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.7M |
| 2 |
Millennium Management
New York
|
-$9.6M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$6.66M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$2.55M |
| 5 |
ICM
IronBridge Capital Management
Oakbrook Terrace,
Illinois
|
-$2.11M |
GHDX Hedge Fund Activity: Q1 2015 in Review
112 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q1 2015, worth a combined $901M — down 6.4% from $963M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GHDX and 13 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 44 added.
The largest buyer was State Street, adding an estimated $5.12M. The largest seller was Fidelity Investments, cutting an estimated $15.7M.
- 112 institutional investors held Genomic Health, Inc. (GHDX) as of Q1 2015, down from 113 in Q4 2014.
- Funds reported $901M of Genomic Health, Inc. stock for Q1 2015, down 6.4% quarter-over-quarter.
- 13 funds opened new Genomic Health, Inc. positions in Q1 2015 and 14 closed out, a net change of -1 holder.
- The largest Genomic Health, Inc. buyer in Q1 2015 was State Street, an estimated $5.12M added.
- The largest Genomic Health, Inc. seller in Q1 2015 was Fidelity Investments, an estimated $15.7M sold.
Based on aggregated 13F filings for Q1 2015.